by The global softgel capsules market size is projected to attain around USD 17.19 billion by 2033 from USD 8.71 billion in 2023 with a CAGR of 7.03% from 2024 to 2033.
Key Points
- North America led the market with the largest market share of 43% in 2023.
- By type, the gelatin-based/animal-based segment has accounted biggest market share in 2023.
- By application, the vitamins and dietary supplements segment held the largest share of the market in 2023.
- By end-use, the nutraceutical companies segment has contributed more than 38% of market share in 2023.
The softgel capsules market has witnessed significant growth in recent years, driven by the rising demand for convenient and easy-to-swallow dosage forms across various industries such as pharmaceuticals, nutraceuticals, and cosmetics. Softgel capsules are gelatin-based shells filled with liquid or semi-solid active ingredients. They offer several advantages over traditional dosage forms, including improved bioavailability, enhanced stability of sensitive ingredients, and better patient compliance. The market is characterized by intense competition among key players, continuous product innovation, and expanding applications in novel therapeutic areas.
Get a Sample: https://www.precedenceresearch.com/sample/3929
Growth Factors
Several factors contribute to the growth of the softgel capsules market. One of the primary drivers is the increasing prevalence of chronic diseases worldwide, leading to higher demand for pharmaceutical products. Softgel capsules provide an ideal delivery system for various drugs, including pain relievers, vitamins, and supplements, due to their ease of administration and rapid absorption. Additionally, the growing consumer awareness regarding preventive healthcare and the importance of dietary supplements fuels the demand for softgel capsules in the nutraceutical sector. Furthermore, advancements in capsule technology, such as the development of vegetarian and enteric-coated softgels, have expanded the market’s growth potential.
Region Insights
The softgel capsules market exhibits a global presence, with key regional markets including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America dominates the market, driven by a well-established pharmaceutical industry, increasing consumer preference for dietary supplements, and favorable regulatory policies. Europe follows closely, with significant contributions from pharmaceutical manufacturing hubs in countries like Germany and the UK. The Asia Pacific region is expected to witness the fastest growth, attributed to rising healthcare expenditure, expanding pharmaceutical infrastructure, and growing awareness about preventive healthcare practices among the population.
Softgel Capsules Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 7.03% |
| Global Market Size in 2023 | USD 8.71 Billion |
| Global Market Size by 2033 | USD 17.19 Billion |
| U.S. Market Size in 2023 | USD 2.81 Billion |
| U.S. Market Size by 2033 | USD 5.54 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Type, By Application, and By End-use |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Softgel Capsules Market Dynamics
Drivers
Several drivers propel the growth of the softgel capsules market. One of the key drivers is the growing demand for consumer-friendly dosage forms, especially among pediatric and geriatric populations who may have difficulty swallowing conventional tablets or capsules. Softgel capsules offer a convenient and palatable alternative, thereby improving patient compliance and medication adherence. Furthermore, the expanding pharmaceutical industry, fueled by the introduction of novel drug formulations and increasing research and development activities, drives the demand for softgel capsules as a preferred dosage form for new drug delivery systems.
Restraints
Despite the promising growth prospects, the softgel capsules market faces certain challenges that may hinder its expansion. One of the primary restraints is the fluctuating prices of gelatin, a key raw material used in softgel capsule manufacturing. Volatility in gelatin prices can impact production costs and profit margins for manufacturers, thereby affecting market growth. Additionally, concerns regarding the use of animal-derived gelatin in traditional softgel capsules have prompted the development of alternative formulations such as vegetarian or plant-based capsules. However, the transition to these alternatives may involve additional costs and regulatory hurdles, posing challenges to market players.
Opportunities
Despite the challenges, the softgel capsules market presents numerous opportunities for growth and innovation. The increasing demand for personalized medicine and targeted drug delivery systems opens avenues for customized softgel formulations tailored to specific patient needs. Moreover, the growing popularity of functional foods and dietary supplements, coupled with the expanding e-commerce sector, provides opportunities for market expansion and penetration into new geographical regions. Furthermore, advancements in capsule technology, such as the incorporation of novel excipients and controlled-release formulations, offer opportunities for product differentiation and market competitiveness. Overall, the softgel capsules market is poised for continued growth, driven by evolving consumer preferences, technological advancements, and expanding applications across diverse industries.
Read Also: Smart Home Healthcare Market Size to Cross USD 212.55 Bn by 2033
Recent Developments
- In May 2022, the launch of SOLFEROL Softgel Capsules, a line of reimbursed vitamin D3 medications, for the treatment of vitamin D insufficiency was announced by Windzor Pharma Ireland Ltd. This product has the broadest array of presentations available on the market, with two distinct strengths: 400 IU for treating expectant and nursing mothers and 20,000 IU for those with severe vitamin D3 deficiency.
- In December 2023, Amneal Pharmaceuticals and Strides Pharma Science Limited announced the launch of Icosapent ethyl acid soft gel capsules, a product that refers VASCEPA. Strides, a multinational pharmaceutical producer, has granted an in-license for the medicine, which Amneal will begin marketing in the fourth quarter of 2023. An ethyl ester of eicosapentaenoic acid (EPA), isicosapent ethyl acid soft gel capsules, 0.5g and 1g, are recommended as a dietary supplement to lower triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Softgel Capsules Market Players
- CAPTEK Softgel International Inc.
- Sirio Pharma Co., Ltd.
- Fuji Capsule
- Thermo Fisher Scientific Inc.
- EyePoint Pharmaceuticals, Inc.
- EuroCaps
- Catalent, Inc.
- Aenova Group
- ProCaps Laboratories, LLC
- Lonza Capsules & Health Ingredientss
- Soft Gel Technologies, Inc.
Segments Covered in the Report
By Type
- Non-Animal-Based
- Gelatin-Based/Animal-Based
By Application
- Anti-Inflammatory Drugs
- Antacid and Anti-Flatulent Preparation
- Antibiotic and Antibacterial Drugs
- Cough and Cold Preparations
- Anti-Anemic Preparations
- Vitamin and Dietary Supplement
- Health Supplement
- Pregnancy
By End-use
- Cosmeceutical Companies
- Nutraceutical Companies
- Pharmaceutical Companies
- Contract Manufacturing Organizations
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
